Gerresheimer (GXI) Given a €55.00 Price Target by Hauck & Aufhaeuser Analysts

Gerresheimer (ETR:GXI) has been assigned a €55.00 ($65.48) price objective by stock analysts at Hauck & Aufhaeuser in a note issued to investors on Wednesday. The brokerage presently has a “sell” rating on the stock. Hauck & Aufhaeuser’s price target would suggest a potential downside of 22.92% from the company’s previous close.

GXI has been the subject of a number of other reports. Credit Suisse Group set a €80.00 ($95.24) target price on Gerresheimer and gave the company a “buy” rating in a research note on Tuesday, October 10th. Goldman Sachs Group set a €69.50 ($82.74) price objective on Gerresheimer and gave the stock a “neutral” rating in a research report on Thursday, October 12th. set a €65.00 ($77.38) price objective on Gerresheimer and gave the stock a “neutral” rating in a research report on Tuesday, October 17th. Independent Research set a €68.00 ($80.95) price objective on Gerresheimer and gave the stock a “neutral” rating in a research report on Wednesday, October 11th. Finally, JPMorgan Chase & Co. set a €87.70 ($104.40) price objective on Gerresheimer and gave the stock a “buy” rating in a research report on Friday, December 29th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of €70.62 ($84.07).

Shares of Gerresheimer (ETR:GXI) opened at €71.35 ($84.94) on Wednesday. Gerresheimer has a 12 month low of €59.97 ($71.39) and a 12 month high of €78.25 ($93.15). The firm has a market capitalization of $2,250.00 and a price-to-earnings ratio of 50.60.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Markets Daily and is owned by of Markets Daily. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.themarketsdaily.com/2018/01/10/gerresheimer-gxi-given-a-55-00-price-target-by-hauck-aufhaeuser-analysts.html.

Gerresheimer Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply